Abstract:Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most frequently mutated oncogene in human cancers with mutations predominantly occurring in codon 12. These mutations disrupt the normal function of KRAS by interfering with GTP hydrolysis and nucleotide exchange activity, making it prone to the GTP-bound active state, thus leading to sustained activation of downstream pathways. Despite decades of research, there has been no progress in the KRAS drug discovery until the groundbreaking discovery of covalently targeting the KRASG12C mutation in 2013, which led to revolutionary changes in KRAS-targeted therapy. So far, two small molecule inhibitors sotorasib and adagrasib targeting KRASG12C have received accelerated approval for the treatment of non-small cell lung cancer (NSCLC) harboring KRASG12C mutations. In recent years, rapid progress has been achieved in the KRAS-targeted therapy field, especially the exploration of KRASG12C covalent inhibitors in other KRASG12C-positive malignancies, novel KRAS inhibitors beyond KRASG12C mutation or pan-KRAS inhibitors, and approaches to indirectly targeting KRAS. In this review, we provide a comprehensive overview of the molecular and mutational characteristics of KRAS and summarize the development and current status of covalent inhibitors targeting the KRASG12C mutation. We also discuss emerging promising KRAS-targeted therapeutic strategies, with a focus on mutation-specific and direct pan-KRAS inhibitors and indirect KRAS inhibitors through targeting the RAS activation-associated proteins Src homology-2 domain-containing phosphatase 2 (SHP2) and son of sevenless homolog 1 (SOS1), and shed light on current challenges and opportunities for drug discovery in this field.

Advances of Detection of KRAS Mutation and Targeted Therapy for Colorectal Cancer

Detection and treatment of K-RAS gene mutation after administration of cetuximab in patients with metastatic colorectal cancer：A case report and literature review

Advances in KRAS mutation inhibition in metastatic colorectal cancer

Recent Advances in Biomarkers for the Targeted Therapy of Metastatic Colorectal Cancer

Detection of K-ras gene mutation in colorectal tumor and relationship with clinicopathological features

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

KRAS Mutation Testing in Metastatic Colorectal Cancer.

Targeting KRAS in Colorectal Cancer

The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers

Targeting KRASG12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments

Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives.

KRAS, a New Target for Precision Medicine in Colorectal Cancer?

Detection of K-ras Mutation in Colorectal Cancer and Its Clinicopathological Significance

Detection of KRAS mutations and their associations with clinicopathological features and survival in Chinese colorectal cancer patients.

Treatment Advancement of Targeted Therapy for Colorectal Cancer

Progress in targeted therapy of KRAS mutations in non-small cell lung cancer

Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches

Colorectal Cancer Patients with Low Abundance of KRAS Mutation May Benefit from EGFR Antibody Therapy

Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS

From bench to bedside: current development and emerging trend of KRAS-targeted therapy

KRAS mutation: from undruggable to druggable in cancer